2 recruiting. 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Recruiting 2 |
Follow Plasma Cell Leukemia (PCL): new trials by email Literature Review of Plasma Cell Leukemia (PCL) trials Research Report on Plasma Cell Leukemia (PCL)
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| CM336 Plus Isa-VR in Newly Diagnosed Primary Plasma Cell Leukemia CM336, Isatuximab, Bortezomib - Plasma Cell Leukemia (PCL) | Phase 2 | Recruiting | Institute of Hematology & Blood Diseases Hospital, China | 24 | 2026-09-15 | 2026-09-18 |
| IL-15-Armored CAR-T Therapy in Relapsed or Refractory Multiple Myeloma and Plasma Cell Leukemia IL-15-armored CAR-T cells - Relapsed/Refractory Multiple Myeloma, Plasma Cell Leukemia (PCL) | Phase 2 | Recruiting | The First Hospital of Jilin University | 25 | 2025-12-29 | 2026-04-03 |
Leukemia, Plasma Cell (2) · Multiple Myeloma (1)
Hematologic Diseases (2) · Hemic and Lymphatic Diseases (2) · Immune System Diseases (2) · Immunoproliferative Disorders (2) · Leukemia (2) · Lymphoproliferative Disorders (2) · Neoplasms (2) · Neoplasms by Histologic Type (2) · Neoplasms, Plasma Cell (2) · Blood Protein Disorders (1) · Cardiovascular Diseases (1) · Hemorrhagic Disorders (1) · Hemostatic Disorders (1) · Multiple Myeloma (1) · Paraproteinemias (1)
Bortezomib (1) · Lenalidomide (1) · isatuximab (1)
Institute of Hematology & Blood Diseases Hospital, China (1) · The First Hospital of Jilin University (1)
China (2)